MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
An Interview With Felix Mahfoud, MD, MA
Prof. Mahfoud breaks down his translational cardiology research focused on the autonomic nervous system and interorgan communication in cardiovascular disease, remaining hurdles and research priorities for renal denervation, his work with the ESC and EAPCI, and more.
Dyspnea in a Diabetic Patient With Previous TAVR
Moderator: Franz X. Kleber, MDPanel: Finn Gustafsson, MD, PhD, and Felix Mahfoud, MD
Next Frontiers in HTN Denervation
Reflections on the next generation of RDN trials and their potential endpoints, how to handle data collection, and new applications beyond renal.
With Felix Mahfoud, MD, MA; Ajay J. Kirtane, MD; and Andrew Sharp, MD
Neuromodulation in Heart Failure: Proven and Emerging Solutions
A summary of the pathophysiologic rationale and latest clinical evidence for the role of interventional neuromodulating therapies in treating heart failure.
By Felix Götzinger, MD; Lucas Lauder, MD; and Felix Mahfoud, MD, MA
Ask The Experts: Lessons From the Renal Denervation Learning Curve
Experts share insights into lessons learned from clinical trials and real-world experience to date and the future of renal denervation.
With Herbert D. Aronow, MD, MPH; Michael Kunz, MD; Lucas Lauder, MD; and Felix Mahfoud, MD
Future of Renal Denervation Considered at EuroPCR
May 23, 2014—At the annual EuroPCR conference, Felix Mahfoud, MD, and Konstantinos Tsioufis, MD, reflected on the potential future role of modulation of the sympathetic nervous system in patients with difficult-to-control hypertension.
Six-Month Data Published From Ablative Solutions’ Peregrine Postmarket Study
February 20, 2020—Ablative Solutions, Inc. announced that 6-month results from the Peregrine postmarket study were published by Professor Felix Mahfoud, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2020;13:471–484).
ESC Issues Consensus Document on Catheter-Based Renal Denervation
April 25, 2013—The European Society of Cardiology (ESC) announced the publication of a European expert consensus document on catheter-based renal denervation.
Medtronic’s Global SYMPLICITY Registry Shows Sustained Lower Blood Pressure After Renal Denervation
June 25, 2020—Medtronic reported new data from the Global SYMPLICITY registry (GSR), which showed that renal denervation (RDN) with the Medtronic Symplicity RDN system significantly reduced blood pressure (BP) in uncontrolled hypertension patients out to 3 years independent of antihypertension medication burden.
ReCor’s Paradise Ultrasound Renal Denervation System Launched in Europe
October 6, 2021—ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the commencement of the launch of the company’s Paradise ultrasound renal denervation system in Europe.
Inari PEERLESS II RCT Will Compare FlowTriever Versus Anticoagulation in PE Patients
May 22, 2023—Inari Medical, Inc. announced the planned enrollment of PEERLESS II, the company’s third randomized controlled trial (RCT) in venous thromboembolism (VTE).
Medtronic’s Symplicity Spyral RDN System Studied at 3 Years in SPYRAL HTN-ON MED Trial
April 4, 2022—Medtronic announced long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial, which demonstrated that patients who were prescribed antihypertensive medications and treated with the company’s Symplicity Spyral renal denervation (RDN) system continued to show durable, clinically significant blood pressure reductions through 3 years.
Medtronic Presents Renal Denervation Data From Global SYMPLICITY Registry and Launches GSR-DEFINE Study
May 18, 2021—Medtronic announced that new clinical data from the Global SYMPLICITY Registry (GSR) indicating that renal denervation (RDN) with the company’s Symplicity system was associated with clinically significant and sustained blood pressure reductions in a real-world population of patients with hypertension (HTN) through 3 years.
EMBRACE to Study Medtronic’s Symplicity Spyral RDN System With Staged PCI
March 31, 2026—Medtronic announced it is supporting the investigator-initiated EMBRACE trial of the company’s Symplicity Spyral renal denervation (RDN).
Medtronic’s SPYRAL GEMINI Multiorgan Denervation Study Begins Enrollment
July 7, 2025—Medtronic announced that the first patient has been treated in its SPYRAL GEMINI global pilot study, which will investigate the safety and potential efficacy of multiorgan denervation (MDN) in patients with uncontrolled hypertension (HTN).
Challenging Cases: What Would You Do?
By Ted E. Feldman, MD, MSCAI, FACC, FESC, and Shakeel A. Qureshi, MD, FRCP, FRCPCH
First-in-Man Feasibility Study Evaluates RenalGuard System to Manage Fluids in Heart Failure Patients
January 5, 2018—RenalGuard Solutions, Inc. announced positive results from a first-in-man (FIM) feasibility study focusing on a novel use of the company's RenalGuard system to manage fluids during diuretic therapy in congestive heart failure patients experiencing fluid overload.
Medtronic’s Symplicity RDN System Assessed in 3-Year GSR DEFINE Data
May 23, 2023—Medtronic announced the findings from two studies supporting radiofrequency (RF) renal denervation (RDN) with the company’s Symplicity system for the treatment of patients with uncontrolled hypertension.
Lesion Assessment and Interventional Heart Failure
By Jozef Bartunek, MD, and Andrew Sharp, MD
Technical Essentials
By Andrea Scotti, MD, and Azeem Latib, MD
